New app turns smartphone into a medical device for detecting infections in transplant patients – at home and at speed
PATIENTS who have had a kidney transplant are benefitting from the latest smartphone technology to improve the way infections are detected and treated.
A cohort of 22 post-transplant patients - who are particularly prone to urinary tract infections (UTIs) - is trialling home-testing kits that are linked to a unique and clinically-approved phone app.
Using the latest in image recognition and artificial intelligence (AI), it transforms the patient’s smartphone into a clinical-grade scanner – with the same pinpoint accuracy as lab-based analysis.
The trial has been developed by our kidney transplant and Future Digital teams in partnership with clinical technology specialists, Healthy.io, and will be formally evaluated later this year.
Previously, at the first sign of infection, these patients would have to make an appointment to visit their GP, give a urine sample for lab diagnosis, and wait – sometimes up to three days - for the results and the start of medication.
Now they simply undertake the same dipstick test in the comfort of their own home in a matter of minutes, usingtheir smartphone camera to capture the readings.
At the touch of a button, these results are then transmitted to our kidney transplant team, who can prescribe appropriate antibiotics – according to our established protocol - straight away.
The team believes that the way this technology has speeded up diagnosis and treatment has prevented hospital admission in some cases.
And because it is so user-friendly, it has also given patients the confidence to self-manage their condition.
Furthermore, initial feedback from our patients has been extremely positive with a score of 88 being reported by the Net Promoter tool analysing client experience and loyalty – in an environment where over 70 is considered world-class.
Our kidney transplant team currently cares for around 700 patients, aged between 20 and 93, from across Salford as well as Wigan, Bolton and Oldham – so the potential benefit is huge.
Consultant nephrologist, Dr Rachel Middleton, said: “With a weakened immune system following transplant, our patients are particularly prone to UTIs.
“Early detection plays an important role in reducing the severity of the infection and the risk of contracting life-threatening conditions, such as sepsis and acute kidney injury (AKI).
“The technology we are testing turns an everyday smartphone into a diagnostic device, transforming the way urine tests are performed.
“It has taken a tried and tested medical tool - the dipstick – and taken it into the 21st century to analyse a range of different infections.”
The kit – known as Dip.io - contains detailed instructions for home-testing and disposable test strips and testing cups.
But the major clinical innovation is a panel of patterns and colours that guides the smartphone camera to read the test strip accurately, regardless of lighting or environment.
This means that unlike many existing at-home lab kits, patients don't have to mail anything back, and they can get results in an instant.
The same process is followed by patients at the end of their course of antibiotics to ensure the treatment has been successful and they are free of infection.
Although in its infancy, the initiative has already triggered interest at the British Transplant Society, which has invited our clinical team to give a presentation at its annual national congress in March.
Given that urine analysis is the second most frequently-conducted diagnostic test, the technology has the capability to benefit patient care in a raft of other conditions.
This trial is among the latest innovations to go live as part of our programme of more than 50 world-class projects being brought to life by our Global Digital Exemplar and Future Digital teams.
Our photo shows kidney transplant clinic team members (from left) consultant nephrologist Dr Rachel Middleton; specialist nurse Lucy Griffiths; and staff nurse Angela Bailey with the home-testing kit being trialled.